LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
LifeStance Health Group, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC and certain selling stockholders for an underwritten public offering of 25,000,000 shares of its common stock under an effective Form S-3 shelf registration. All 25,000,000 shares are being sold by the selling stockholders, so the company did not receive any proceeds from this offering.
Under the same agreement, LifeStance agreed to repurchase 7,000,000 of these shares from the underwriter at the same price per share paid to the selling stockholders, and the underwriter received no compensation on the repurchased shares. The offering closed on March 2, 2026, and Ropes & Gray LLP provided a legal opinion on the shares, filed as an exhibit.
LifeStance Health Group, Inc. is registering 25,000,000 shares of its common stock for resale by selling stockholders under a prospectus supplement.
The offering is a resale by selling stockholders; the Company will receive no proceeds from these sales and intends, subject to the offering closing, to repurchase 7,000,000 shares at the underwriter purchase price and retire those repurchased shares. Shares outstanding used for disclosure were 389,783,210 shares as of February 17, 2026. The underwriter agreed to purchase the shares from the selling stockholders at $7.01 per share, and delivery is expected on or about March 2, 2026.
LifeStance Health Group, Inc. is registering 25,000,000 shares of common stock for resale by selling stockholders under a preliminary prospectus supplement dated February 25, 2026.
The Company will not receive proceeds from these sales; it intends, subject to the offering closing, to repurchase 7,000,000 shares of the shares being sold at the same per-share price paid to the selling stockholders and retire those repurchased shares. Shares outstanding were 389,783,210 as of February 17, 2026. The filing lists a Nasdaq last sale price of $7.14 per share on February 24, 2026.
LifeStance Health Group provides a large outpatient mental health platform and describes its business model, scale and key risks in this annual report. As of December 31, 2025, it employed 8,040 licensed clinicians across 33 states, operating 572 centers and offering virtual care.
In 2025, clinicians treated more than 1.0 million unique patients through approximately 9.0 million visits, generating revenue primarily on a per‑visit basis. For the year, 90% of revenue came from commercial in‑network payors, 5% from government payors, 4% from self‑pay and 1% from non‑patient services.
The company highlights benefits for patients, clinicians, payors and physician partners, but also emphasizes risks, including dependence on reimbursement rates, concentration in major payors such as UnitedHealthcare and Elevance Health, clinician recruiting and retention challenges, regulatory complexity and competition in a fragmented mental health market.
LifeStance Health Group, Inc. insider Stephanie Carin Eken, the company’s Chief Medical Officer, filed an initial ownership report on Form 3. This filing formally records her status as an executive officer of LifeStance Health but does not list any specific share transactions or holdings in the excerpt provided.
LifeStance Health Group reported strong fourth-quarter and full-year 2025 results, returning to profitability and authorizing a major share repurchase. Fourth-quarter revenue rose 17% to $382.2 million, with full-year revenue up 14% to $1,424.3 million, driven by 18% higher visit volumes and a 9% larger clinician base of 8,040.
Income from operations reached $18.1 million in the quarter and $24.1 million for the year, while net income was $11.7 million in Q4 and $9.7 million for 2025, compared with losses in 2024. Adjusted EBITDA grew 49% in Q4 to $48.8 million and 32% for the year to $157.7 million, with margins improving to 12.8% in Q4.
The company generated $146.2 million in operating cash flow and ended 2025 with $248.6 million of cash and $265.9 million of net long-term debt. The board approved a $100 million share repurchase program, and 2026 guidance calls for revenue of $1.615–$1.655 billion and Adjusted EBITDA of $185–$205 million. Executive Chairman Kenneth Burdick will transition to non-executive chairman in March 2026.
FMR LLC and Abigail P. Johnson report beneficial ownership of 46,706,784.10 shares of LifeStance Health Group Inc. common stock, representing 12.0% of the class as of December 31, 2025.
FMR LLC has sole voting power over 46,693,362.00 shares and sole dispositive power over 46,706,784.10 shares. One or more other persons may receive dividends or sale proceeds, but no other person holds more than five percent of the outstanding common stock.
LifeStance Health Group’s Executive Vice President of Practice Operations filed an amended Form 3 updating her insider holdings. She now reports beneficial ownership of 282,495 shares of common stock, including 254,122 unvested restricted stock units, each convertible into one share. The amendment corrects an earlier filing that had inadvertently overstated her holdings by 17,039 shares, which were also mistakenly reflected on subsequent Forms 4.
LifeStance Health Group, Inc. director filed a Form 4 reporting several sales of common stock through affiliated entities in December 2025. On 12/12/2025, Vitthal LLC and Shama LLC each sold 39,815 shares of LifeStance common stock at a weighted average price of $7.01 per share, with individual trades ranging from $7.00 to $7.045.
On 12/15/2025, Vitthal LLC sold 6,186 shares and Shama LLC sold 6,185 shares at a weighted average price of $7.00, with trades between $7.00 and $7.01. Following these transactions, the reporting person is shown as beneficially owning 1,382,175 shares indirectly through Vitthal LLC, 1,498,975 shares indirectly through Shama LLC, 57,619 shares directly, and 36,363 shares indirectly through Alpine Glow Capital, while disclaiming beneficial ownership beyond their pecuniary interests.
LifeStance Health Group, Inc. (LFST) disclosed that an executive sold company stock. On 11/21/2025, the Executive Vice President, Practice Operations reported selling 57,240 shares of LifeStance common stock at a weighted average price of $6.43 per share, in multiple trades between $6.41 and $6.50. After these sales, the executive beneficially owns 261,292 shares of LifeStance common stock. The filing notes that full trade details for each price within the range are available upon request.